Literature DB >> 15113682

Structural characterization of the antigenic O-polysaccharide in the lipopolysaccharide produced by Actinobacillus pleuropneumoniae serotype 14.

Malcolm B Perry1, Leann L MacLean.   

Abstract

The antigenic O-polysaccharide of the lipopolysaccharide produced by Actinobacillus pleuropneumoniae serotype 14 was shown by chemical analysis and 1D and 2D nuclear magnetic resonance methods to be a high-molecular-mass polymer of a repeating disaccharide unit composed of a chain of (1-->5)-linked beta-D-galactofuranose (beta-D-Galf) residues substituted at their O-2 positions by alpha-D-galactopyranose residues (D-Galp) (1:1): [Formula: see text].

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15113682     DOI: 10.1016/j.carres.2004.03.011

Source DB:  PubMed          Journal:  Carbohydr Res        ISSN: 0008-6215            Impact factor:   2.104


  4 in total

1.  Identification of conserved surface proteins as novel antigenic vaccine candidates of Actinobacillus pleuropneumoniae.

Authors:  Xiabing Chen; Zhuofei Xu; Lu Li; Huanchun Chen; Rui Zhou
Journal:  J Microbiol       Date:  2012-12-30       Impact factor: 3.422

2.  Characterization of the antigenic lipopolysaccharide O chain and the capsular polysaccharide produced by Actinobacillus pleuropneumoniae serotype 13.

Authors:  Leann L MacLean; Malcolm B Perry; Evguenii Vinogradov
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

3.  A Unique Capsule Locus in the Newly Designated Actinobacillus pleuropneumoniae Serovar 16 and Development of a Diagnostic PCR Assay.

Authors:  Janine T Bossé; Yanwen Li; Rita Sárközi; Marcelo Gottschalk; Øystein Angen; Katerina Nedbalcova; Andrew N Rycroft; László Fodor; Paul R Langford
Journal:  J Clin Microbiol       Date:  2017-01-04       Impact factor: 5.948

4.  Experimental identification of Actinobacillus pleuropneumoniae strains L20 and JL03 heptosyltransferases, evidence for a new heptosyltransferase signature sequence.

Authors:  Susana Merino; Yuriy A Knirel; Miguel Regué; Juan M Tomás
Journal:  PLoS One       Date:  2013-01-30       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.